Pharmaceutical News and Articles

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill MK-8527

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally Merck (NYSE MRK), known as MSD outsi

Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid

Shorla Oncology ( Shorla ), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Adagene Inc. ( Adagene or the Company ) (Nasdaq ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced o

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable Biosimilar to NovoLog

FDA Sends Warning Letters to Companies Selling Illegal Opioid Compound

The U.S Food and Drug Administration has issued seven warning letters to companies illegally marketing products containing 7-hydroxymitragynine (7-OH), which is

No Risks Seen With Early Childhood Exposure to Aluminum-Adsorbed Vaccines

Early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disord

FDA Approves Gardenia-Based Blue Dye for Use in Foods and Drinks

TUESDAY, July 15, 2025 A natural blue food coloring made from gardenia fruit has been approved by the U.S. Food and Drug Administration (FDA). The additive dubb

Most Major Ice Cream Brands Will Remove Synthetic Dyes by 2028

TUESDAY, July 15, 2025 About 90 of the ice cream sold in the U.S. will no longer contain artificial dyes by 2028, federal health officials announced. Roughly 40

Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients

Kidney transplant recipients receiving the investigational cellular product MDR-101 achieved functional immune tolerance for more than two years, according to a